These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 11789961)

  • 1. Rationale for the use of platelet aggregation inhibitors in PAD patients.
    Agnelli G
    Vasc Med; 2001; 6(3 Suppl):13-5. PubMed ID: 11789961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy.
    Hiatt WR
    J Intern Med; 2002 Mar; 251(3):193-206. PubMed ID: 11886478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence with antiplatelet therapy and ADP-receptor antagonists.
    Easton JD
    Cerebrovasc Dis; 2003; 16 Suppl 1():20-6. PubMed ID: 12698015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet therapy in peripheral arterial disease.
    Aronow WS
    Curr Drug Targets Cardiovasc Haematol Disord; 2004 Sep; 4(3):265-7. PubMed ID: 15379619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease.
    Montalescot G
    Clin Cardiol; 2000 Nov; 23 Suppl 6(Suppl 6):VI-18-22. PubMed ID: 11129682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clopidogrel: a review of its use in the prevention of atherothrombosis.
    Jarvis B; Simpson K
    Drugs; 2000 Aug; 60(2):347-77. PubMed ID: 10983738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
    Hankey GJ; Sudlow CL; Dunbabin DW
    Cochrane Database Syst Rev; 2000; (2):CD001246. PubMed ID: 10796426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients.
    Hacke W
    Cerebrovasc Dis; 2002; 13 Suppl 1():22-6. PubMed ID: 11803184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data.
    Diener HC; Bogousslavsky J; Brass LM; Cimminiello C; Csiba L; Kaste M; Leys D; Matias-Guiu J; Rupprecht HJ
    Cerebrovasc Dis; 2004; 17(2-3):253-61. PubMed ID: 14981346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet agents in the prevention of cardiovascular morbidity and mortality in older patients with vascular disease.
    Aronow WS
    Drugs Aging; 1999 Aug; 15(2):91-101. PubMed ID: 10495069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet therapy in populations at high risk of atherothrombosis.
    Faxon DP; Nesto RW
    J Natl Med Assoc; 2006 May; 98(5):711-21. PubMed ID: 16749646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
    Tran H; Anand SS
    JAMA; 2004 Oct; 292(15):1867-74. PubMed ID: 15494585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    CAPRIE Steering Committee
    Lancet; 1996 Nov; 348(9038):1329-39. PubMed ID: 8918275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The basis of platelets: platelets and atherothrombosis: an understanding of the lack of efficacy of aspirin in peripheral arterial disease (PAD) and diabetic patients].
    Drouet L; Bal dit Sollier C; Henry P
    Drugs; 2010 Nov; 70 Suppl 1():9-14. PubMed ID: 20977287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet drugs in secondary prevention after acute myocardial infarction.
    Thizon-de-Gaulle I
    Rev Port Cardiol; 1998 Dec; 17(12):993-7. PubMed ID: 9973860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
    Bhatt DL; Flather MD; Hacke W; Berger PB; Black HR; Boden WE; Cacoub P; Cohen EA; Creager MA; Easton JD; Hamm CW; Hankey GJ; Johnston SC; Mak KH; Mas JL; Montalescot G; Pearson TA; Steg PG; Steinhubl SR; Weber MA; Fabry-Ribaudo L; Hu T; Topol EJ; Fox KA;
    J Am Coll Cardiol; 2007 May; 49(19):1982-8. PubMed ID: 17498584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.
    Berger JS; Krantz MJ; Kittelson JM; Hiatt WR
    JAMA; 2009 May; 301(18):1909-19. PubMed ID: 19436018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet therapy in the prevention of ischaemic stroke.
    Verry M; Panak E; Cazenave JP
    Nouv Rev Fr Hematol (1978); 1994 Jun; 36(3):213-28. PubMed ID: 7971242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
    Mohler ER
    Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S1-6. PubMed ID: 19213065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk reduction with clopidogrel in the management of peripheral arterial disease.
    Nayak KR; Cavendish JJ
    Vasc Health Risk Manag; 2007; 3(3):289-97. PubMed ID: 17703636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.